恒瑞医药7月24日公告,公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发的关于HRS-1893片的《药物临床试验批准通知书》,将于近期开展临床试验。申请的适应症为拟用于治疗射血分数保留的心力衰竭。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.